Stocks · News reference
Rhythm Pharmaceuticals Announces Positive Phase 2 Results for Bivamelagon
Rhythm Pharmaceuticals reported positive Phase 2 clinical trial results for bivamelagon in patients with acquired hypothalamic obesity and plans to initiate a Phase 3 trial.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
AstraZeneca Proposes $10 Billion Acquisition of Rhythm Pharmaceuticals
AstraZeneca has reportedly made a non-binding offer to acquire Rhythm Pharmaceuticals for approximately $10 billion, or up to $134 per share.
AstraZeneca Makes $10 Billion Takeover Offer for Rhythm Pharmaceuticals
AstraZeneca has reportedly submitted a $10 billion acquisition offer for Rhythm Pharmaceuticals at $124 per share.
Rhythm Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 21.67%
'AstraZeneca Made $10 Billion Offer For Rhythm Pharmaceuticals; Rhythm Specializes In Treatments For Metabolic Conditions And Severe Obesity' - WSJ Exclusive
NICE Issues Positive Guidance for IMCIVREE in Adults with Bardet-Biedl Syndrome
The National Institute for Health and Care Excellence (NICE) has updated its guidance to include adults living with genetically confirmed Bardet-Biedl syndrome (BBS) for IMCIVREE treatment.